| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$129 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:17AM |
$0.778 |
$0.740 |
fallen by
4.82%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- Island Pharmaceuticals Limited focuses on urgent viral diseases and biosecurity threats.
- They are developing ISLA-101 and Galidesivir as part of their strategy.
- ISLA-101 is used for dengue fever prevention and treatment.
- Galidesivir is an antiviral molecule targeting multiple RNA viruses.
- The company held $14.18 million in cash as of March 2026.
- Net cash used in operations was $1.3 million for the quarter.
- Payments to related parties totaled $139,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beach Energy Limited (BPT) ORDINARY FULLY PAID |
Energy |
$2,464 |
FY26 Third Quarter Activities Report
|
28 Apr 2026 9:16AM |
$1.195 |
$1.080 |
fallen by
9.62%
|
|
BPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Beach Energy's production increased by 7% to 4.8 MMboe quarter-on-quarter.
- Strong performance from the Waitsia Gas Plant, reaching 94% of nameplate capacity.
- Challenges included severe rains impacting production in Cooper Basin and Western Flank.
- Sales revenue stood at $419 million, a 6% decrease from the previous quarter.
- Average realised oil price rose by 19% to A$125 per barrel.
- Liquidity increased to $974 million, with net gearing reduced to 11%.
- Production guidance revised to 19.4 – 20.3 MMboe for FY26.
- Successful drilling campaigns were conducted, with 100% success in the Cooper Basin JV.
- Moomba Central Optimisation project aims to enhance infrastructure and production.
- New acreage awarded in the Taroom Trough and Cooper Basin for future exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ausquest Limited (AQD) ORDINARY FULLY PAID |
Materials |
$72 |
Quarterly Activities and Cashflow Report
|
28 Apr 2026 9:15AM |
$0.045 |
$0.044 |
fallen by
2.22%
|
|
AQD - Price-sensitive ASX Announcement
Full Release
Key Points
- Cangallo Copper-Gold Project in Peru shows significant mineralization.
- Significant copper and gold grades confirmed in drilling results.
- Plans to commence diamond drilling and further RC drilling.
- Preparation for exploration activities in Australia, including Balladonia and Coober Pedy.
- Quarter-end cash position of $10.2 million.
- Funding includes contributions from South32 for Australian projects.
- Ongoing assessment of new opportunities within Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$53 |
Quarterly Activities & Cashflow Report
|
28 Apr 2026 9:14AM |
$0.325 |
$0.233 |
fallen by
28.46%
|
|
BIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Activated Probiotics surpassed 1 million boxes sold.
- Biome is on track for 100 million doses delivered by Q4 FY26.
- Activated Probiotics is the fastest-growing probiotic brand in Australia.
- National campaign launched in Canada for Activated Probiotics.
- Net cash increase at bank for Q3 FY26 to $3,387k.
- BMB18 clinical trial to commence and patent application filed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$17 |
Trading Halt
|
28 Apr 2026 9:14AM |
$0.019 |
$0.016 |
fallen by
15.79%
|
|
RMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading in Red Mountain Mining Limited (ASX: RMX) has been halted at RMX's request.
- The trading halt is due to a material agreement relating to a new Tungsten Project.
- RMX is planning, executing, and completing a capital raising.
- The halt will last until normal trading on Thursday, 30 April 2026, or until the announcement is released.
- The company is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 1414 Degrees Limited (14D) ORDINARY FULLY PAID |
Industrials |
$61 |
SiNTL Update - Drone & UAV Market Engagement to Commence
|
28 Apr 2026 9:14AM |
$0.018 |
$0.120 |
risen by
566.67%
|
|
14D - Price-sensitive ASX Announcement
Full Release
Key Points
- SiNTL outperforms traditional graphite and silicon batteries.
- SiNTL offers improved energy capacity, faster charging, and maintained cycle stability.
- 1414 Degrees is engaging with the drone and UAV market to utilize SiNTL.
- The drone market is forecasted to reach US$160 billion by 2030.
- SiNTL is designed for easy integration with existing battery manufacturing processes.
- Special aluminium coating on SiNTL anodes mitigates volume expansion.
- 1414 Degrees is advancing the SiNTL silicon nanoparticle anode program.
- SiNTL provides a lower-cost upgrade to graphite anodes.
- Focus on scale-up and manufacturing process optimization for SiNTL.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| European Lithium Limited (EUR) ORDINARY FULLY PAID |
Materials |
$832 |
EUR to combine with CRML implied valuation $0.58 per share
|
28 Apr 2026 9:14AM |
$0.285 |
$0.485 |
risen by
70.18%
|
|
EUR - Price-sensitive ASX Announcement
Full Release
Key Points
- European Lithium Limited (ASX: EUR) has entered into a non-binding indicative agreement with Critical Metals Corp (CRML).
- The proposal involves CRML acquiring 100% of European Lithium's issued securities via a scheme of arrangement for scrip consideration.
- Each EUR shareholder will receive CRML scrip valued at A$0.58 per EUR share held.
- The proposal offers a significant premium for EUR shareholders, representing a 137% premium over the last closing price.
- EUR shareholders are expected to own approximately 45% of the combined entity post-transaction.
- The transaction aims to provide liquidity benefits, with EUR shares being exchanged for a more liquid NASDAQ-listed CRML stock.
- The proposal includes consolidation of ownership interest in the Tanbreez Rare Earths project.
- The proposal is currently non-binding and subject to various conditions including due diligence and board recommendations.
- European Lithium’s Board has formed an independent committee to evaluate the proposal.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Proteomics International Laboratories Ltd (PIQ) ORDINARY FULLY PAID |
Health Care |
$22 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:13AM |
$0.265 |
$0.135 |
fallen by
49.06%
|
|
PIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic review completed and discontinuation of the DTC business model.
- Engagement with potential distribution partners in Australia and the USA.
- Continued validation and refinement of Promarker Endo and Promarker Eso assays.
- Organisational restructure resulting in cost savings exceeding $1 million.
- Leadership changes including the appointment of Mr David Morris as CEO and Managing Director.
- Cash outflows from operations totaled $2.6 million for the quarter ending 31 March 2026.
- Received $0.7 million from the exercise of PIQO options.
- Cash and cash equivalents stood at $5.7 million as of 31 March 2026.
- Net cash used in operating activities was $3.6 million year to date.
- Financial discipline and commercial strategy highlighted as a priority.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$188 |
72% Heavy Rare Earth ratio and a Second Zircon Hf Product
|
28 Apr 2026 9:13AM |
$1.750 |
$1.430 |
fallen by
18.29%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- HREE/LREE separation achieved using Heavy Liquid Separation (HLS) technique
- 72% HREO:TREO ratio achieved in pre-concentrate testing
- High-grade HREE pre-concentrate identified in coarse fraction
- Potential non-Chinese supply chain for heavy rare earths and strategic metals
- Second Zircon Hafnium product identified in finer fractions
- Significant mineral resource estimates for the North Stanmore Project
- Potential for Scandium and Gallium as byproducts
- Ongoing focus on strategic defense metals production
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$707 |
Update - Notification of buy-back - RF1
|
28 Apr 2026 9:13AM |
$3.470 |
$3.390 |
fallen by
2.31%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,328 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:12AM |
$1.310 |
$1.350 |
risen by
3.05%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC is progressing through Phase 1a/1b clinical studies for Polycystic Kidney Disease (PKD) and Autosomal Dominant Optic Atrophy (ADOA).
- The company reported enrolment and dosing advancements in its clinical trials, with plans for further studies in Q2 2026.
- PYC's financial position as of March 31, 2026, includes $667 million in cash and a $23 million R&D rebate.
- The company reported $16,666,000 in research and development expenses for the quarter.
- PYC is working on drug candidates for Retinitis Pigmentosa type 11 (RP11) and Phelan-McDermid Syndrome (PMS).
- The Appendix 4C cash flow report outlines a net cash use of $16,262,000 in operating activities for the quarter.
- PYC's financing activities brought in a net $563 million due to equity securities issuance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pivotal Metals Limited (PVT) ORDINARY FULLY PAID |
Materials |
$21 |
Horden Lake Strategy Update
|
28 Apr 2026 9:11AM |
$0.015 |
$0.016 |
risen by
6.67%
|
|
PVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Mineral Resource update is in progress to enlarge the existing resource.
- A scoping study is advancing, targeting a large open-pit operation.
- Metallurgical testwork aims to improve recovery into clean concentrates.
- Horden Lake holds a strategic position with jurisdictional advantages in Québec.
- Resource growth potential with under-explored regional opportunities.
- The project is positioned against a backdrop of limited global copper development pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Central Petroleum Limited (CTP) ORDINARY FULLY PAID |
Energy |
$51 |
Quarterly Activities Report & Appendix 5B
|
28 Apr 2026 9:11AM |
$0.078 |
$0.068 |
fallen by
12.82%
|
|
CTP - Price-sensitive ASX Announcement
Full Release
Key Points
- Steady production at Palm Valley and Mereenie fields.
- Approval for two new wells at Palm Valley to increase capacity.
- New multi-year Gas Supply Agreement secured.
- Increased sales revenue due to higher gas prices and volumes.
- Challenges in oil sales due to specification constraints.
- Net cash inflow from operating activities.
- Significant cash outflow for investing activities.
- Increased loan facility for drilling support.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$525 |
Weekly NTA 24 April 2026
|
28 Apr 2026 9:10AM |
$1.785 |
$1.900 |
risen by
6.44%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:10AM |
$0.450 |
$0.435 |
fallen by
3.33%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic A$2.4 million investment from ZYBT
- FDA confirmation of a single pivotal trial pathway for Elate Ocular®
- Continued advancement in CMC preparations for Phase 3
- Net operating cash outflow of A$0.792 million
- Closing cash balance of A$2.246 million
- Multiple funding strategies to support Phase 3 program
- Key milestone of starting Phase 3 trial in H2 CY 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neometals Limited (NMT) ORDINARY FULLY PAID |
Materials |
$29 |
Application for quotation of securities - NMT
|
28 Apr 2026 9:10AM |
$0.041 |
$0.033 |
fallen by
19.51%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$208 |
Compelling 90% Success Rate for Remplir in Real World Study
|
28 Apr 2026 9:10AM |
$0.850 |
$0.765 |
fallen by
10%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Remplir™ demonstrates an overall treatment success rate of 89.7%.
- The study involved 66 patients aged 14 to 82 years.
- Majority of procedures were performed in the upper limb.
- No post-treatment complications reported, indicating high safety and biocompatibility.
- 90.3% of motor nerve repairs resulted in functional muscle recovery.
- 89.4% of nerve decompression procedures showed significant symptom improvement.
- The study supports commercial growth in the U.S. and upcoming European markets.
- Orthocell is focused on expanding Remplir's adoption globally.
- Regulatory approval expected in H2 CY26.
- More than 300 surgeons in Australia and 49 in the U.S. are using Remplir.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| eMetals Limited (EMT) ORDINARY FULLY PAID |
Materials |
$6 |
Mineral Range Tungsten Project, Field Activities Commence
|
28 Apr 2026 9:10AM |
$0.007 |
$0.007 |
fallen by
7.14%
|
|
EMT - Price-sensitive ASX Announcement
Full Release
Key Points
- Field activities commenced at Mineral Range Tungsten Project.
- Focus on high-grade tungsten mineralization.
- Project comprises 109 mineral claims over 2,072 acres.
- Initial work involves geological mapping and rock chip sampling.
- High-grade tungsten results from rock chip samples reported.
- Use of modern exploration techniques including UV scheelite scanning.
- Targeting known mineralized zones around historical mines.
- Project uses contact metasomatic processes as exploration framework.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tambourah Metals Ltd (TMB) ORDINARY FULLY PAID |
Materials |
$10 |
Beatty Park Sth EIS Co-Funding and T1 Drilling
|
28 Apr 2026 9:09AM |
$0.047 |
$0.040 |
fallen by
14.89%
|
|
TMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Tambourah Metals awarded $180,000 EIS co-funding grant.
- Initial T1 aircore drilling shows potential for gold system.
- 75-hole program at Beatty Park Sth returned promising results.
- Planning for additional drilling at T2 anomaly and Baxter’s.
- Program aims to explore extensions of Beatty Park Sth gold target.
- Historical data and geophysical surveys used to refine targets.
- Continued analysis to understand gold mineralisation structures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$599 |
Weekly NTA 24.04.2026
|
28 Apr 2026 9:06AM |
$2.580 |
$2.690 |
risen by
4.26%
|
|
| Mammoth Minerals Limited (M79) ORDINARY FULLY PAID |
Materials |
$30 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:05AM |
$0.073 |
$0.054 |
fallen by
26.03%
|
|
M79 - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities report for March 2026
- Appendix 5B cash flow report included
- Details about cash flows from operating, investing, and financing activities
- Net cash used in operating activities amounted to $241,000
- No significant investments or financing activities reported
- Cash and cash equivalents at the end of the period were $12,330,000
- No outstanding loan facilities or financing arrangements reported
- Payments to related parties and associates totaled $121,000
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TerraCom Limited (TER) ORDINARY FULLY PAID |
Energy |
$128 |
Quarterly Activities Report
|
28 Apr 2026 9:05AM |
$0.074 |
$0.070 |
fallen by
5.41%
|
|
TER - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities report for the period ended 31 March 2026.
- March quarter impacted by adverse weather conditions affecting logistics.
- FY26 guidance maintained at 1.6 Mt despite disruptions.
- Completion of a $60 million entitlement offer to strengthen balance sheet.
- Significant management changes including resignation of key executives.
- Strong recovery forecasted with contracted sales for the June quarter.
- FOB operating costs expected to moderate as conditions improve.
- Partnership progress with Wintime Energy Group Co. Ltd.
- Operations in Australia and South Africa continue with strategic focus on cost control.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,148 |
Update - Notification of buy-back - AFI
|
28 Apr 2026 9:05AM |
$6.650 |
$6.550 |
fallen by
1.50%
|
|
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$20 |
Initial Director's Interest Notice - Michael Sistenich
|
28 Apr 2026 9:05AM |
$0.044 |
$0.041 |
fallen by
6.82%
|
|
| Dorsavi Ltd (DVL) ORDINARY FULLY PAID |
Health Care |
$54 |
DVL Expands Robotics Strategy into Next-Gen Exoskeletons
|
28 Apr 2026 9:04AM |
$0.035 |
$0.045 |
risen by
28.57%
|
|
DVL - Price-sensitive ASX Announcement
Full Release
Key Points
- dorsaVi Ltd targets exoskeleton systems as a strategic application.
- The company's technology includes wearable motion sensors and neuromorphic semiconductors.
- Exoskeleton systems provide real-time movement monitoring and adaptive control.
- Projected exoskeleton market to exceed USD 2 billion by 2033.
- Technology applicable to broader robotics, including collaborative and surgical robots.
- Expansion leverages existing sensor intelligence platform and RRAM development.
- Focus on human-robot collaboration space with real-time AI-driven decisions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
